Aquestive(US:AQST) Globenewswire·2026-03-18 17:28Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [4][6]. Group 1: Legal Investigation - The law firm is reminding investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Aquestive [4]. - The complaint alleges that Aquestive and its executives made false or misleading statements and failed to disclose the true state of the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [6]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price fell by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [7]. Group 3: Investor Participation - The court-appointed lead plaintiff is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation on behalf of the class [8]. - Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8].